Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
Latest
AstraZeneca to advance Oxford’s COVID-19 vaccine with $1bn investment
AstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read more
Pfizer’s gene therapy promising for Duchenne muscular dystrophy (DMD)
Pfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read more
CEPI to fund Novavax COVID-19 vaccine with up to $388 Million
CEPI has increased its investment with up to $388 million for the Novavax COVID-19 (NVX‑CoV2373) vaccine development and manufacturing. Phase
Read more
FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read more
BioMed, Utrecht University and Erasmus discover antibody blocking SARS-CoV-2 in cells
Scientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read more
Roche’s COVID-19 antibody test gets FDA emergency authorisation
Swiss pharma giant Roche has received Emergency Use Authorisation (EUA) from the FDA for its latest COVID-19 antibody test –
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
FDA issues emergency authorisation for remdesivir to treat COVID-19
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for emergency use of Gilead’s remdesivir
Read more
Remdesivir effective in U.S. NIH trial for advanced COVID-19
Remdesivir, an investigational nucleotide analog with broad-spectrum antiviral activity developed by the Californian biopharmaceutical company Gilead Sciences, has shown promising
Read more